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ABSTRACT
Interleukin (IL)-7 promotes both thymopoiesis and mature T lymphocyte survival and proliferation in experi-
mental murine models of hematopoietic stem cell (HSC) transplantation. Because HSC products for transplan-
tation also may contain IL-7–responsive mature T lymphocytes, we examined whether IL-7 is necessary for the
induction of GVHD after allogeneic bone marrow transplantation (BMT). Lethally irradiated C57BL6J (B6) and
B6.IL-7-/- (both H2Kb) recipient mice were co-transplanted with T cell–depleted (TCD) bone marrow cells and
lymph nodes (LNs) from either congenic B6.SJL (CD45.11) or allogeneic BALB/c (H2Kd) donor mice. After
transplantation, the recipient mice were subcutaneously injected with either human recombinant IL-7 or phos-
phate-buffered saline (PBS) for 60 days. No evidence of GVHD was detected in the congenic recipients or in the
allogeneic B6/IL-7-/- recipients treated with PBS; in contrast, significantly increased rates of GVHD-related
mortality and morbidity were found in the allogeneic B6.IL-7-/- recipients treated with IL-7. The proliferation
and number of donor T cells were significantly lower at day 30 post-BMT in the PBS-treated B6.IL-7-/- recip-
ients compared with the IL-7–treated B6.IL-7-/- mice. These experiments demonstrate that IL-7 is an important
factor in the development of GVHD, presumably by supporting the survival, proliferation, and possibly
activation of alloreactive donor-derived T cells in the recipients.
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Although allogeneic bone marrow transplantation
(BMT) is a potentially life-saving treatment for pa-
tients with hematologic, oncologic, or immunologic
diseases, graft-versus-host disease (GVHD) continues
to be a potentially serious complication that limits the
efficacy of transplantation. GVHD is initiated when
donor T lymphocytes are activated by host alloanti-
gens. On activation, inflammatory cytokines produced
by donor T cells induce proliferation and differentia-
tion of various effector cells, including anti-host helper
and cytotoxic T cells (CTLs), macrophages, and natu-
ral killer cells, which cause damage to target organs
such as liver, gut, lung, and skin [1-6]. A number of
therapeutic measures, including T cell depletion16(TCD) and immunosuppressive therapies, have been
used to prevent GVHD post-BMT [7].
The post-BMT period is marked by profound im-
munodeficiency, making newly transplanted patients
susceptible to various bacterial, viral, and fungal infec-
tions [8,9]. GVHD, immunosuppressive procedures or
therapies to prevent or treat GVHD, and the time re-
quired for donor stem cells to develop into T lympho-
cytes contribute to the post-BMT immunodeficiency.
Although TCD can prevent GVHD, it increases the
degree of post-BMT immune deficiency because of
the additional time required for the development of
new T lymphocytes from donor-derived progenitors.
In addition, the nonspecific immunosuppressive ef-
fects of drugs to prevent or treat GVHD also may
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reconstitution after BMT is further hindered by im-
paired function of the thymic microenvironment
caused by age, pre-BMT conditioning, and GVHD
itself [10-12]. Methods to enhance the development
of T lymphocytes and immune reconstitution are
critical to solving the problem of post-BMT immune
deficiency.
IL-7, along with Kit ligand (KL; stem cell factor),
is the major lymphopoietic cytokine produced in the
thymus and bone marrow (BM) compartment
[13,14]. IL-7 induces proliferation, differentiation,
and survival of immature T lymphocytes throughout
development. During normal T cell development in
the thymus, IL-7 produced by thymic epithelial cells
binds to the cognate IL-7 receptors expressed on the
surface of immature T lymphoid progenitor cells.
IL-7 stimulates the differentiation of immature
CD3-CD4-CD8- (triple-negative) thymocytes to later
stages, ultimately resulting in the development of ma-
ture CD41CD8- or CD4-CD81 T cells. The impor-
tance of IL-7 for thymopoiesis is demonstrated by
mice with targeted mutations of the IL-7, IL-7 recep-
tor a, or common g chain (gc) genes, dogs with X-
SCID (gc mutations), or humans with X-SCID, all
of which have defective thymopoiesis and impaired
ability to produce T lymphocytes [15-18]. We and
others have shown that administration of recombinant
human IL-7 corrects the thymopoietic defects ob-
served after histocompatible BMT, suggesting that
post-BMT IL-7 administration may be a potential
therapy for post-BMT immunodeficiency [19,20].
Other effects of IL-7 have raised concerns about its
safety in the context of allogeneic BMT, however. Be-
sides immature lymphoid progenitors, such as com-
mon lymphoid progenitors and thymocytes, the IL-7
receptor is expressed by mature T lymphocytes [21].
The IL-7R expressed by mature T lymphocytes medi-
ates several important biological effects that are likely
to be clinically relevant. Homeostatic proliferation of
naı¨ve CD41 and CD81 T lymphocytes depends on
combined T cell receptor (TCR) recognition of self-li-
gands and IL-7R signaling. IL-7Ra-/- T lymphocytes
do not proliferate normally in a normal host, whereas,
conversely, normal T lymphocytes do not undergo ho-
meostatic proliferation in IL-7-/- hosts [22-24]. Stimu-
lation through IL-7R also increases expression of the
bcl-2 anti-apoptotic protein, thereby increasing sur-
vival of mature T lymphocytes [24-26]. Furthermore,
IL-7 may function as a co-factor for T lymphocyte ac-
tivation by stimulating production of Th1 cytokines
such as IL-2, IFN-g, and IL-12 [27-29].
In allogeneic transplantation, the effects of IL-7 on
mature T lymphocytes might cause or exacerbate
GVHD by either promoting the proliferation or sur-
vival of alloreactive donor mature T cells, or by in-
creasing their activation state. Studies of the effectsof IL-7 on GVHD have yielded conflicting results
[30,31]. Alpdogan et al. [30] using several mouse
models of allogeneic BMT and IL-7 dosing schedules,
reported that post-BMT administration of IL-7 did
not cause GVHD, whereas Sinha et al. [31], using
somewhat different models, showed that IL-7 treat-
ment exacerbated GVHD.
To clarify the role of IL-7 in the pathogenesis of
GVHD, we performed experiments to determine
whether IL-7 is necessary for the development of
GVHD after allogeneic BMT. We hypothesized that
endogenous or exogenous IL-7 is required for mainte-
nance, proliferation, and possibly activation of donor
T lymphocytes can mediate GVHD. Using genetic
models of IL-7 deficiency, we demonstrate that either
endogenously produced or exogenously administered
IL-7 is necessary for the development of GVHD,
most likely by promotion of the survival and prolifer-
ation of alloreactive T lymphocytes. The results sug-
gest that the therapeutic use of IL-7 to improve
immune reconstitution in an allogeneic setting may
exacerbate GVHD.
MATERIALS AND METHODS
Mice
Female C57BL/6J (H-2Kb, CD45.2), male B6.SJL
(H-2Kb, CD45.1), male BALB/c (H-2Kd Thy 1.2), and
male BALB/c (H-2Kd Thy 1.1) mice (age 8-10 weeks)
were purchased from the Jackson Laboratory (Bar
Harbor, ME). A breeding colony of IL-7-/- mice on
a C57BL/6J background (H-2Kb, CD45.2, B6.IL-
7-/-) was established from founder mice kindly
provided by Dr Richard Murray (DNAX Research
Institute, Palo Alto, CA). Protocols for animal care
and BMT were approved by the Children’s Hospital
Los Angeles Research Institute Animal Care Commit-
tee and the University Committee on Use and Care of
Laboratory Animals at Stanford University.
BMT Procedure
Female C57BL/6J (H-2Kb) recipient mice were
given 2 separate doses of radiation from a 137Cs source
at 128 cGy/minute (700 cGy on day -1 and 600 cGy on
day 0) before transplantation. In each experiment, con-
trol mice received irradiation without subsequent
BMT, to verify that the doses of radiation were mar-
row-ablative. BM cells were harvested from the femur
and tibia of male congenic (histocompatible) B6.SJL
(H-2Kb, CD45.1), allogeneic BALB/c (H-2Kd Thy
1.2), or allogeneic BALB/c (H-2Kd Thy 1.1) donor
mice by perfusion, after the mice were sacrificed by
CO2 narcosis. The donor marrow was depleted of ma-
ture T lymphocytes by immunomagnetic depletion,
using rat anti-mouse Thy 1, CD4, and CD8 monoclo-
nal antibodies (mAb; Pharmingen, San Diego, CA) and
sheep anti-rat antibodies conjugated to beads (Dynal,
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pleted cells was determined by flow cytometric analysis
(FACS) to ensure a frequency of mature T lympho-
cytes in the infused marrow of\ 0.1%.
GVHD was induced by administration of T lym-
phocytes derived from lymph nodes (LNs) of donor
mice at the same time as BMT. Mesenteric, axillary,
and inguinal LN were collected, minced, and filtered
through nylon mesh to eliminate adherent cells. After
completion of pre-BMT irradiation on day 0, 1  106
T cell–depleted (TCD) BM cells and 4  106 LN cells
were resuspended in phosphate-buffered saline (PBS;
Bio Whittaker, Walkerville, MD) and transplanted
into each recipient through tail vein injection (0.3
mL total volume). After transplantation, mice were
housed in sterilized micro-isolator cages and given
normal chow and autoclaved water containing tetracy-
cline HCl 20 mg/mL (Goldline, Miami, FL) for the
first 2 weeks post-BMT and filtered water thereafter.
Administration of Recombinant Human IL-7
Recombinant human IL-7 (rhIL-7; R&D Systems,
Minneapolis, MN), resuspended in PBS, was asepti-
cally administered to the BMT recipients by subcuta-
neous injection at a dose of 500 ng twice daily for 30
or 60 days or until sacrifice [19]. The control mouse
groups were injected with normal saline according to
the same schedule.
Assessment of GVHD
The degree of GVHD severity was assessed using
the clinical scoring system described by Cook et al.
[33]. Each animal undergoing BMT animal was scored
weekly for 5 parameters (weight loss, skin integrity, fur
texture, mobility, and posture) on a scale of 0 to 2
(0, absent or normal; 1, mildly abnormal; 2, severely
abnormal). The GVHD clinical index was the sum of
the scores for individual criteria.
Histological Analysis
Wax-coated tissue sections from small intestine
and skin were cut into 5-mm-thick sections, mounted
onto slides, fixed in 10% formalin, and stained with
hematoxylin and eosin. The tissue sections were inde-
pendently examined in a blinded manner for evidence
of GVHD by 2 of the authors [5].
Flow Cytometry
Peripheral blood lymphocytes or single-cell sus-
pensions of splenocytes or LN cells were prepared by
lysing the red blood cells with lysis buffer containing
ammonium chloride (Gibco Life Technologies, Carls-
bad, CA). Here, 1 105 cells were stained with optimal
concentrations of fluorescein isothiocyanate, phycoer-
ithrin, allophycocyanin, or PerCP-conjugated anti-
Thy1.1, Thy 1.2, CD3, CD4, CD8, CD69, H2Kb,H2Kd, or isotype control monoclonal antibodies
(Pharmingen, San Diego, CA). After staining, the cells
were washed twice in PBS and analyzed with the
FACSCalibur analyzer (Becton Dickinson, Franklin
Lakes, NJ). In some experiments, donor LN cells
were labeled with carboxyfluorescein diacetate succi-
nimidyl ester (CFSE) before transplantation to mea-
sure the proliferation in vivo of the cells after
transplantation. Donor LN cell proliferation was as-
sessed by measuring separate peaks of decreased inten-
sity of CFSE fluorescence on successive cell division by
FACS analysis of the labeled donor CD4 or CD8
T cell population.
Statistical Analyses
Analyses of survival rates were performed using
Wilcoxon’s log-rank test. Comparisons of donor cell
recovery, weight loss, and GVHD scoring were done
using 2-way analysis of variance. Differences of
between groups of different immunophenotypic popu-
lations of cells after transplant were analyzed by a
2-tailed t-test with unequal distributions. P values #
.05 were considered statistically significant.
RESULTS
IL-7 Is Necessary for GVHD-Related Mortality
After Allogeneic BMT
To assess whether IL-7 is necessary for the devel-
opment of GVHD, we measured the survival rate of
recipient B6 or B6.IL-7-/- mice after transplantation
of congenic or allogeneic BM and LN cells. Radia-
tion-treated (1300 cGy) B6 and B6.IL-7-/- mice (H-
2Kb) were co-transplanted with 1 106 TCD BM cells
and 4  106 LN T lymphocytes from either congenic
B6.SJL (H-2Kb) or allogeneic BALB/c mice (H-2Kd).
After BMT, either PBS or rhIL-7 (500 ng twice a day
subcutaneously) was administered to the transplant re-
cipients for 60 days. A schedule of continuous admin-
istration of IL-7 was chosen to ensure that IL-7 was
present at all times post-BMT, because it was un-
known when IL-7 might exert effects on the co-trans-
planted mature T lymphocytes.
Figure 1 shows survival of the congenic and alloge-
neic B6 and B6.IL-7-/- recipients. The survival of the
congenic recipients was 100%, regardless of whether
they were normal B6 or B6.IL-7-/- mice. Administra-
tion of IL-7 to the congenic B6 or B6.IL-7-/- recipients
did not decrease survival. Thus, neither the presence
nor absence of endogenous IL-7, or the administration
of exogenous IL-7, had any effect on survival in the
congenic setting.
In contrast to the results observed in congenic re-
cipients, the presence or absence of IL-7 affected the
outcome of allogeneic BMT. In the first 25 days after
allogeneic BMT, there was no difference between the
B6 and B6.IL-7-/- recipients. As expected with the fully
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BMT. The B6 or B6.IL-7-/- recipients that had received 1300 cGy TBI received either 1  106 TCD BM and 4  106
LN cells from BALB/c donor mice, or similar cell numbers of LN and BM cells from congenic B6.SJL donors
(CD45.1), and were then treated with recombinant human IL-7 (500 ng twice a day via subcutaneous injection) for 60
days. Survival over the 150 days after BMT is shown. Survival of all wild-type allogeneic B6 recipients was significantly
lower than that of the congenic recipients (*P\ .002). Survival of the PBS-treated B6.IL-7-/- allogeneic recipients was sig-
nificantly lower than that of congenic B6.IL-7-/- recipients (*P\ .03). The difference between the IL-7– and PBS-treated
allogeneic B6.IL-7-/- recipients is significant (*P\ .002).H2-incompatible BALB/c to B6 model, the mortality
of either IL-7– or PBS-treated normal B6 recipients
was approximately 70%, with deaths continuing to oc-
cur throughout the 150-day observation period. Al-
though IL-7 injections induced higher mortality in
normal allogeneic B6 recipients (75% vs 65%), the dif-
ference between the IL-7– and PBS-treated wild-type
mice was not statistically significant. However, in the
IL-7- recipients treated with PBS, GVHD-related
mortality diminished to 41% at day 150. Similar to
the normal B6 allogeneic recipients, some mortality
occurred in the PBS-treated B6.IL-7-/- allogeneic re-
cipient mice in the first 25 days after BMT. No further
deaths were observed after this initial post-BMT pe-
riod, however. In contrast, mortality of IL-7–treated
allogeneic B6.IL-7-/- and B6 recipients continued
throughout the 150-day observation period.
To further quantify the effects of IL-7 treatment
on the clinical status of mice undergoing BMT, the
mice were evaluated for GVHD based on a clinical
scoring system for 6 weeks after transplantation [31].
As expected, both congenic B6 and B6.IL-7-/- recipi-
ents treated with either IL-7 or PBS showed no signs
of GVHD-related morbidity (Figure 2). In contrast,
allogeneic-normal B6 recipients displayed significant
weight loss and other evidence of GVHD compared
with the congenically transplanted controls (not
shown). The overall clinical grading of GVHD inthe IL-7–treated B6 mice was more severe (P\ .05)
(Figure 2A). Similar to the results observed in the con-
genic recipients, the allogeneic B6.IL-7-/- recipient
mice treated with PBS demonstrated no clinical evi-
dence of GVHD (Figure 2B). However, administra-
tion of IL-7 to the allogeneic B6.IL-7-/- recipients
resulted in GVHD-related morbidity resembling that
observed in the allogeneically transplanted B6 recipi-
ents (P \ .012). The difference in mortality and
GVHD score in the IL-7–treated and PBS-treated
allogeneic B6.IL-7-/- recipients, combined with the
lack of clinical toxicity of IL-7 after congenic trans-
plantation, indicates that deaths occurring in the
IL-7–treated allogeneic BMT recipients was GVHD-
related.
Absence of Histological GVHD in IL-7-/- Allogeneic
BMT Recipients
GVHD target organs were examined to determine
whether IL-7 caused any histological damage. The ir-
radiated animals received either IL-7 or PBS from day
1 to day 30 after allogeneic BMT. On day 30, sections
from the small intestine and skin were analyzed for
evidence of GVHD. The tissue samples from the
PBS- or IL-7–treated congenic recipients showed no
evidence of tissue inflammation. The results differ
somewhat from those of Sinha et al. [31], who noted
increased tissue inflammation in syngeneic BMT
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treated with IL-7 that did not undergo BMT. Com-
pared with the congenic recipients, however, the IL-7
and PBS-treated allogeneic normal B6 recipients
demonstrated histological evidence of GVHD, and
the severity of the tissue inflammation did not appear
to differ between the IL-7–treated and PBS-treated
hosts (Figure 3A). The intestines exhibited villus
blunting, lamina propria inflammation, crypt destruc-
tion, and mucosal atrophy in both the IL-7– treated
and PBS-treated groups of allogeneic B6 recipients.
The mice also had cutaneous GVHD, with infiltration
of lymphocytes, hyperkeratosis, and hair loss. In the
absence of IL-7 in the B6.IL-7-/- hosts, the histological
Figure 2. Treatment with IL-7 increased GVHD-related morbidity
after allogeneic BMT. The severity of GVHD was determined by
GVHD clinical grading system with scoring for 5 clinical criteria:
percentage of weight loss, skin integrity, posture, mobility, and fur
texture [31]. Clinical signs were graded on a scale of 0 to 2, (0, absent;
1, moderate; 2, severe), and the individual signs were summed.
Shown are GVHD clinical index scores at 4 and 6 weeks for B6 re-
cipients (A) and B6.IL-7-/- recipients (B). Differences between the
IL-7–treated and PBS-treated allogeneic recipients are P\ .05 in
both B6 recipients and B6.IL-7-/- recipients ()).samples from the allogeneic B6 recipients did not ap-
pear to be different from those of the congenic B6 re-
cipients. The allogeneic B6.IL-7-/- allogeneic
recipients treated with IL-7 displayed the same
GVHD-related histological features seen in the allo-
geneic B6 recipients (Figure 3B). These findings dem-
onstrate that IL-7 was important in GVHD-related
tissue damage and inflammation, but was not intrinsi-
cally pathogenic in the histocompatible setting.
IL-7 Is Necessary for Maintenance of Donor T Cells
in the Periphery of Recipient Mice
Because the development of GVHD depends on
donor-derived mature T cells, we investigated whether
IL-7 treatment altered the number of donor-derived
mature CD4 and CD8 T cells in the spleen, LN, and
peripheral blood lymphocytes after allogeneic trans-
plantation. IL-7 or PBS-treated allogeneic recipients
were analyzed at days 10 and 30 after transplantation.
Figure 4 shows the number of donor-derived CD4 and
CD8 T cell populations at day 10 and day 30 in the pe-
ripheral blood, LN, and spleen of the mice treated with
PBS and those treated with IL-7. Administration of
IL-7 to normal B6 recipients increased the numbers
of donor-derived mature T cells 1.2- to 3-fold in all
sites (Figure 4A, C, E). The effects of IL-7 on mature
T cell numbers were observed as early as day 10, before
the generation of thymic-derived T cells would be ex-
pected. To distinguish newly generated donor T cells
from adoptively transferred T lymphocytes, BALB/c
TCD BM cells (H2Kd Thy1.11) and BALB/c LN T
cells (H2Kd Thy1.21) were co-transplanted into allo-
geneic B6.IL-7-/- (H2Kb Thy1.21) recipients treated
with daily rhIL-7. The percentages of the donor-de-
rived T cells generated from the transplanted marrow
were significantly lower than that of adoptively trans-
ferred LN cells in the thymus, spleen, and LN of the
recipient animals at day 18 posttransplantation (data
not shown). Therefore, the increase in T cell numbers
likely reflected IL-7–induced proliferation of the
adoptively transferred mature T cells.
The PBS-treated B6.IL-7-/- recipients exhibited
significantly lower donor T cell numbers in all 3 lym-
phoid compartments compared with the normal recip-
ients (Figure 4B, D, F). Low numbers of donor CD4
and CD8 cells were detected in the peripheral blood
of B6.IL-7-/- mice treated with PBS at day 10, but
were 2- to 8-fold less frequent than those in normal
B6 recipients (Figure 4A, B). The number of T cells
detected in the lymph nodes of the B6.IL-7-/- recipi-
ents was 100- to 1000-fold lower than those in the nor-
mal B6 recipients (Figure 4C, D). Similarly, the
number of splenic T cells was 10- to 30-fold lower in
the B6.IL-7-/- recipients. By day 30 after transplanta-
tion, the number of donor-derived T cells in the
PBS-treated B6.IL-7-/- mice was almost nil. Thus, in
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from the recipients were analyzed at day 30 after BMT. Representative tissue samples from each group of mice were stained
with hematoxylin and eosin. The tissue sections of skin and small intestine from the PBS-treated and IL-7–treated congenic
BMT plus LN recipients and the PBS-treated allogeneic IL-7-/- recipients demonstrated normal histology. The tissue sec-
tions from allogeneic wild-type B6 recipients treated with PBS or IL-7 and allogeneic B6.IL-7-/- recipients treated with IL-
7 showed evidence of GVHD, with lymphocytic infiltration and inflammation in the gut sections. Shown are hematoxylin
and eosin staining of skin or gut sections from B6 (A) and B6.IL-7-/- (B) recipients of either allogeneic or congenic LN and
TCD BM.the absence of IL-7, adoptively transferred mature T
lymphocytes did not survive (Figures 4B, D, F and 5).
We then investigated whether the defect in lym-
phocyte survival could be rescued by administration
of exogenous IL-7. IL-7 treatment significantly in-
creased the numbers of donor-derived mature T cells
in the B6.IL-7-/- recipients (Figures 4B, D, F and 5).
The number of donor-derived T lymphocytes after
IL-7 treatment was lower in the B6.IL-7-/- recipients
than in the normal B6 recipients treated with either
PBS or IL-7. This suggests that the bolus schedule
of IL-7 administration is not as efficient at mediating
T cell survival compared with endogenously produced
IL-7. Overall, the data support the hypothesis that IL-
7 is necessary to maintain transplanted mature T cells,
including allogeneic cells, in the periphery [19,
23-25,32].
Importance of IL-7 in Proliferation of Allogeneic
T Lymphocytes
Because naı¨ve mature T lymphocytes are known to
undergo homeostatic proliferation after interactions
with self-peptides, we investigated whether therewere phenotypic differences between T lymphocytes
that proliferated after allogeneic or congenic trans-
plantation [23-25]. We analyzed the expression of
CD69 as an activation marker, because up-regulation
of CD69 has been reported during activation-induced
T cell proliferation, including that of alloreactive cells
[33,34]. Mice were co-transplanted with TCD BM and
CFSE-labeled donor LN T cells. Using H2Kd to gate
on the donor cells and CFSE to mark the proliferating
T cells in the allogeneic recipients, we analyzed the ex-
pression of CD69. In the congenic recipients, expres-
sion of CD69 was low to absent in the proliferating
donor-derived (CD45.11) T cells (Figure 6A, B).
The expression of CD69 in the dividing CD4 and
CD8 LN-derived T cells was also analyzed in the allo-
geneic recipients (Figure 6A, B). Most proliferating
donor CD41 or CD81 T cells in the allogeneic recip-
ients had increased levels of CD69 expression. The dif-
ferences in CD69 expression are consistent with CD69
expression marking proliferating alloreactive T cells,
whereas CD69 expression was not induced during ho-
meostatic proliferation of nonalloreactive cells, a con-
cept proposed by Alpdogan et al. [32].
22 B. Chung et al.Figure 4. Administration of IL-7 resulted in increased number of donor CD4 and CD8 T cells in blood, LNs, and spleen after allogeneic BMT.
Donor-derived peripheral lymphocyte numbers in B6 and B6.IL-7-/- recipients sacrificed 10 or 30 days after allogeneic transplantation with
BALB/c LN and TCD BM cells were analyzed. Shown are numbers of donor CD4 and CD8 T cells in peripheral blood (A and B), LN
(C and D), and spleen (E and F) of B6 and B6.IL-7-/- recipients at days 10 and 30. )Significant differences (P\ .05) between the PBS- and
IL-7–treated groups.IL-7 has been shown to both act as a co-factor for
T cell activation and increase the survival of activated
T lymphocytes [24]. We studied the effects of IL-7
on the survival of activated alloreactive T cells after
transplantation to determine whether IL-7 enhanced
the survival of activated allogeneic T cells in vivo. Al-
logeneic marrow and CFSE-labeled LN cells from
BALB/c donors were transplanted into B6 and
B6.IL-7-/- recipients, treated with either IL-7 or
PBS. At day 10, donor-derived T cells in the lymph no-
des of the recipient mice were analyzed by gating on
H2Kd1 cells. The frequency of donor-derived T lym-
phocytes expressing CD69 was used to measure the ef-
fects of IL-7 on activation of T lymphocytes in vivo.
No differences were observed in the frequency of acti-
vated CD4 or CD8 T lymphocytes in the B6 or B6.IL-
7-/- recipients (Figure 6C, D). In normal B6 recipients,
IL-7 treatment did not increase the frequency of acti-
vated T cells. The absolute number of activated T lym-
phocytes was higher in the IL-7–treated B6 recipients;
although the difference was not statistically significant(data not shown). The total number of T lymphocytes
was lower in the B6.IL-7-/- recipients treated with PBS
compared with either the B6- or IL-7–treated B6.IL-
7-/- recipients (Figure 4). However, the frequency of
activated T lymphocytes in the PBS-treated B6.IL-
7-/- recipients was similar to that of both the B6- and
the IL-7–treated B6.IL-7-/- recipients (Figure 6D).
The absolute number of activated T lymphocytes in
the PBS-treated B6.IL-7-/- recipients was significantly
lower than that in the IL-7–treated B6.IL-7-/- recipi-
ents (Figure 6E). These findings indicate that IL-7 is
necessary for the survival and proliferation of the allor-
eactive T lymphocytes, but do not appear to be neces-
sary for their activation.
DISCUSSION
The present study investigated whether IL-7 is
necessary for the development of GVHD. Based on
previous data indicating that naı¨ve T lymphocytes re-
quire IL-7 for proliferation and survival cells, we
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of donor T lymphocytes that cause GVHD. We
treated normal B6 and B6.IL-7-/- mice with IL-7 or
PBS after myeloablative radiation and transplantation
of either congenic or allogeneic BM and LN cells.
Similar to the results observed in the congenic recipi-
ents, we found no evidence of GVHD in the B6.IL-7-/-
allogeneic recipients that did not receive exogenous
IL-7. On the other hand, administration of IL-7 to
the B6.IL-7-/- recipients restored their sensitivity to
the allogeneic cells, thereby decreasing their survival
from 59% to 15%. IL-7 treatment also modestly de-
creased the survival of the normal B6 mice after alloge-
neic BMT. Although the survival rate was similar in all
groups of mice for the first 25 days after transplanta-
tion, only the congenic recipients and the PBS-treated
B6.IL-7-/- allogeneic recipients survived without
GVHD afterward. Confounding our analysis is the
possibility that T lymphopenia itself increased the sus-
ceptibility to GVHD [35]. Nevertheless, the absence
of IL-7 protected allogeneic recipients from GVHD,
as demonstrated by the increased survival rate ofFigure 5. Progressive disappearance of donor-derived allogeneic T
lymphocytes in the absence of IL-7. After allogeneic transplantation
with BALB/c LN and TCD BM cells, donor T cells from the periph-
eral blood of B6.IL-7-/- recipient mice treated with IL-7 or PBS were
gated and stained for CD4 and CD8 at days 10 and 30.
24 B. Chung et al.Figure 6. IL-7 is required for IL-7 administration to maintain activated donor T cells in the LN during allogeneic pro-
liferation at day 10. 1 106 TCD BM and 4  106 CFSE-labeled LN cells from either congenic or allogeneic donors
were transplanted into either lethally irradiated B6 or B6.IL-7-/- recipients. At day 10, most of the proliferating CFSE-
labeled congenic (CD45.11) donor CD4 (A) and CD8 (B) T cells in lymph nodes of the B6 recipients did not express
the CD69 activation marker, whereas the allogeneic (H2Kd) donor cells were predominantly CD691. The frequency of
IL-7 in Experimental Graft-Versus-Host Disease 25PBS-treated B6.IL-7-/- recipients compared with allo-
geneic B6 recipients. The very poor survival rate of
B6.IL-7-/- allogeneic recipients treated with IL-7 com-
pared with B6 recipients treated with IL-7 may reflect
the combined effects of host lymphopenia plus post-
BMT IL-7 treatment. Histological examination at
day 30 showed that skin and gut tissues from IL-7–
and PBS-treated congenic recipients and PBS-treated
allogeneic B6.IL-7-/- recipients displayed no evidence
of acute GVHD. The overall GVHD clinical index
score of PBS-treated B6.IL-7-/- recipients was signifi-
cantly lower than that of the IL-7–treated B6.IL-7-/-
recipients. IL-7 deprivation prevented GVHD
through decreased proliferation and survival of all
transplanted CD41 and CD81 T lymphocytes, pre-
sumably including alloreactive T lymphocytes that
cause GVHD. The death of the transplanted cells
was slow, with complete disappearance of the donor-
derived cells from the periphery not occurring until
approximately day 25-30 post-BMT.
Almost all donor T lymphocytes disappeared from
the PBS-treated B6.IL-7-/- recipients, indicating that
both alloreactive and non–host reactive T lymphocytes
were susceptible to cell death in the absence of IL-7.
Alpdogan et al. [32] recently reported that alloreactive
T lymphocytes express no or little IL-7Ra from
hour 16 to day 8 posttransplantation; however, our
experimental results indicate that the alloreactive T
lymphocytes in the fully major histocompatibility
complex–mismatched BALB/c to B6 model are depen-
dent on IL-7. Although the discrepancy might reflect
technical differences in the GVHD models used in
the respective experiments, the results can be recon-
ciled with those of Alpdogan et al. [32] if either
IL-7Ralow/- alloreactive T lymphocytes are still depen-
dent on IL-7 or if a later differentiation stage of the
alloreactive T lymphocytes is IL-7–dependent. It is
possible that the mAb staining used to detect IL-
7Ra1 cells is unable to detect low levels of biologically
relevant IL-7Ra. Survival signals through IL-7R may
require a smaller number of receptors than the limits
of detection of the anti- IL-7Ra antibody used by Alp-
dogan et al [32]. It is also possible that IL-7Ra was re-
expressed on alloreactive T cells at a later time point
than the day 8 analyses reported by Alpdogan et al. [32].
Besides the pro-survival effects of IL-7 on naı¨ve T
lymphocytes, IL-7 also has been reported to be neces-
sary for proliferation of naı¨ve T cells in conditions of
homeostatic expansion [36,37]. Adoptive transfer of
congenic T cells to IL-7-/- mice resulted in decreased
proliferation and eventual loss of the cells [23]. We hy-pothesized that IL-7 also may play a crucial role in the
peripheral expansion of donor allogeneic mature T
cells [38]. We found that the frequency of activated
CD691T lymphocytes was similar in the allogeneically
transplanted B6 and B6.IL-7-/- recipients. The absolute
number of donor-derived T lymphocytes, including
the activated CD691 cells, declined over the first 25
days after transplantation in the absence of IL-7, at
which point the T cell numbers were too low to allow
further analysis. The recovery of proliferating activated
donor T cells from the lymph nodes was significantly
lower in PBS-treated B6 IL-7-/- mice than in the IL-7
treated B6/IL-7-/- recipients at day 10. Thus, the role
of IL-7 in the development of the GVHD response is
likely related to its proliferative and pro-survival effects,
not to its co-activator function.
The experiments extend and contrast with the
work of Alpdogan et al. [30] and Sinha et al. [31],
who evaluated the effects of posttransplantation IL-7
administration on GVHD in various models of murine
BMT recipients. Whereas the former observed no ef-
fects of IL-7 treatment on GVHD, the latter reported
striking differences in the frequency of GVHD and in-
creased sensitivity to differing doses of alloreactive T
lymphocytes. There are potentially confounding tech-
nical differences in our study and those of Alpdogan
et al. [30], Sinha et al. [31]. Whereas Alpdogan et al.
administered IL-7 in their GVHD experiments
from day -1 to day 113 via a mini-osmotic pump,
Sinha et al. administered IL-7 intraperitoneally. We
prefer subcutaneous injection of IL-7 to use of the
mini-osmotic pump, because previous studies with
mini-pump delivery of IL-7 failed to show even thy-
mopoietic effects in a histocompatible BMT model,
although such effects are readily observed after subcu-
taneous injection [19,39]. The discrepant results seen
in analyses of thymopoiesis led to questions about
whether the IL-7 can be stably delivered by a mini-
pump over 14 days. Furthermore, in our experiments,
we administered IL-7 every day post-transplantation,
because we were uncertain when IL-7 dependence of
alloreactive T lymphocytes might occur.
It is likely that the limited survival and expansion of
alloreactive T cells in the absence of IL-7 can be over-
come by transplantation of sufficient numbers of allo-
reactive cells. Sinha et al. [31] demonstrated that the
increased severity of GVHD after IL-7 treatment
was directly proportional to the number of allogeneic
T cells transplanted. Although clinical and histological
GVHD was not detected in PBS-treated IL-7-/- allo-
geneic recipients, their mortality rate (41%) was stilldonor-derived CD4 or CD8 T cells in the lymph nodes that expressed CD69 after allogeneic transplantation was not sig-
nificantly changed by the IL-7 treatment of either B6 (C) or B6.IL-7-/- (D) recipients. (E) IL-7 treatment of the B6.IL-7-/-
allogeneic recipients increased the absolute number of activated (CD691) donor-derived CD4 and CD8 T lymphocytes
(*P\ .02 for PBS vs IL-7).
=
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genic recipients. Similar to the results of the present
experiments, Tan et al. [23] have demonstrated that
the complete disappearance of transplanted T cells in
an IL-7-/- recipient takes at least 2 weeks. Therefore,
it is possible that the early mortality observed in the
PBS-treated IL-7-/- allogeneic recipients was related
to these animals’ higher doses of alloreactive T cells,
which overcame the decreased T cell survival caused
by lack of IL-7. Consistent with this explanation, all
PBS-treated IL-7-/- allogeneic recipients that survived
the first 25 days became long-term survivors and ex-
hibited no evidence of GVHD.
In the present experiments, the survival rate of IL-
7–treated normal B6 allogeneic mice was lower than
that of the PBS-treated control mice, but was not sta-
tistically significant. Nevertheless, IL-7 treatment in-
creased the number of T lymphocytes and activated
T lymphocytes in the normal B6 recipients. The rela-
tively modest effect on mortality suggests that the en-
dogenous production of IL-7 from the PBS-treated
allogeneic B6 recipients was sufficient to maintain
the survival of alloreactive T cells. Peripheral IL-7
levels due to endogenous production have been re-
ported to be elevated after allogeneic BMT [40].
The experimental demonstration of the impor-
tance of IL-7 for both survival and proliferation of al-
logeneic T lymphocytes may allow synthesis of
previous observations regarding IL-7 levels, lympho-
penia, and GVHD. Several studies have demonstrated
that peripheral IL-7 levels are significantly increased in
lymphopenic hosts [38,41,42]; for example, Bolotin
et al. [41] found that patients with severe combined im-
munodeficiency syndrome undergoing BMT had high
circulating levels of IL-7, which normalized after en-
graftment and development of normal donor T lym-
phocytes [41]. Subsequent studies by Fry et al. [38],
Llano et al. [42], and Napolitano et al. [43] demon-
strated that circulating IL-7 levels also were increased
in lymphopenic patients with human immunodefi-
ciency virus infection. The mechanisms by which lym-
phopenia result in increased circulating levels of IL-7
are unclear. Two possible mechanisms are either that
IL-7 levels vary because of consumption by IL-7R–
bearing lymphocytes, or that peripheral cells that reg-
ulate IL-7 production are actively inhibited by a factor
produced by T lymphocytes. The variation in IL-7
levels is likely an important mechanism for regulation
of homeostatic proliferation, which has been noted to
occur under lymphopenic conditions, that is, when
levels of IL-7 are high.
GVHD or GVHD-like autoimmune illnesses have
been noted to occur more readily in lymphopenic hosts
than in nonlymphopenic hosts [35]. Lymphocytic infil-
tration of organs has been observed in neonatally thy-
mectomized mice and nude mice that have been
engrafted with neonatal thymuses from a normal donor[44,45]. Assuming that the inverse relationship be-
tween T lymphocyte numbers and IL-7 levels can be
generalized, IL-7 levels likely are higher in lympho-
penic hosts than in nonlymphopenic hosts. The higher
IL-7 levels in lymphopenic hosts may increase the pro-
liferation of T lymphocytes and predispose to the ex-
pansion of alloreactive or autoreactive T cells.
The dependence of GVHD on the presence of IL-
7 and the apparent increased risk of GVHD in recipi-
ents of extrinsic IL-7 suggest potential risks in the use
of IL-7 to enhance immune reconstitution after hema-
topoietic stem cell transplantation. Although the pos-
itive effects of IL-7 on thymopoiesis and expansion
of naı¨ve T lymphocyte populations by homeostatic
proliferation would be expected to increase immune
function, our findings indicate that the use of rhIL-7
after allogeneic BM and mature T cell transplantation
leads to maintenance of donor mature T cells and
likely is responsible for the development of GVHD.
The clinical testing of IL-7 therapies to enhance im-
mune reconstitution in the allogeneic setting must be
carefully designed to minimize the risk of GVHD,
for example, by testing in the autologous transplant
or TCD allogeneic settings [20,33,46]. Conversely,
blockade of the IL-7–signaling pathways may be a use-
ful strategy for eliminating donor alloreactive T cells
after transplantation [47].
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